

Progyny Overview

Safe Harbor Statement

Forward-Looking Statements

This presentation includes forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on our management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, statements regarding our positioning to successfully manage the impact of COVID-19, including variants, and the associated economic uncertainty on our business, our financial outlook for full year 2021, our client and member outlook for 2021, our ability to retain existing clients and acquire new clients, and our business strategy, plans, goals and expectations concerning our market position, future operations, and other financial and operating information. The words "may," "believes," "anticipates," "estimates," "estimates," "estimates," "estimates," "continues," "could," "will," "future," "project," and the negative of these or similar terms and phrases are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, without limitation, risks related to the ongoing impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of fertility procedures and other impacts to the business; failure to meet our publicly announced guidance or other expectations about our business; competition in the market in which we operate; our history of operating losses and ability to sustain profitability in the future; our limited operating history and the difficulty in predicting our future results of operations; our ability to attract and retain clients and increase the adoption of services within our client base; the loss of any of our largest client accounts; changes in the technology industry; changes in the health insurance market; negative publicity in the health benefits industry; lags, failures or security breaches in our computer systems or those of our vendors; a significant change in the utilization of our solutions; our ability to offer high-quality support; positive references from our existing clients; our ability to develop and expand our marketing and sales capabilities: the rate of growth of our future revenues: the accuracy of the estimates and assumptions we use to determine the size of target markets: our ability to successfully manage our growth; unfavorable conditions in our industry or the United States economy, such as conditions resulting from outbreaks of contagious diseases, including COVID-19 and variants; reductions in employee benefits spending; seasonal fluctuations in our sales; the adoption of new solutions and services by our clients or members; our ability to innovate and develop new offerings; our ability to adapt and respond to the medical landscape, regulations, client needs, requirements or preferences; our ability to maintain and enhance our brand; our ability to attract and retain members of our management team, key employees, or other qualified personnel; our ability to maintain our company culture; our ability to maintain our Center of Excellence network of healthcare providers; our strategic relationships with and monitoring of third parties; our ability to maintain or any disruption of our pharmacy distribution network; our relationship with key pharmacy program partners or any decline in rebates provided by them; our ability to maintain our relationships with benefits consultants; exposure to credit risk from our members; risks related to government regulation; risks related to potential sales to government entities; our ability to protect our intellectual property rights; risks related to any litigation against us; risks related to acquisitions, strategic investments, partnerships, or alliances; federal tax reform and changes to our effective tax rate; the imposition of state and local state taxes; our ability to utilize a significant portion of our net operating loss or research tax credit carryforwards; our ability to develop or maintain effective internal control over financial reporting and the increased costs of operating as a public company. For a detailed discussion of these and other risk factors, please refer to our filings with the Securities and Exchange Commission (the "SEC"), including in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and subsequent reports that we file with the SEC which are available at http://investors.progvnv.com and on the SEC's website at https://www.sec.gov.

Forward-looking statements represent our management's beliefs and assumptions only as of the date of our August 5, 2021 press release and is not being confirmed or updated herein. Our actual future results could differ materially from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons. Actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Non-GAAP Financial Measures

In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), this press release and the accompanying tables include the non-GAAP financial measures Adjusted EBITDA and Adjusted EBITDA margin. Adjusted EBITDA margin are supplemental financial measures that are not required by, or presented in accordance with, GAAP. We believe that Adjusted EBITDA and Adjusted EBITDA margin, when taken together with our GAAP financial results, provides meaningful supplemental information regarding our operating performance and facilitates internal comparisons of our historical operating performance on a more consistent basis by excluding certain items that may not be indicative of our business, results of operations or outlook. In particular, we believe that the use of Adjusted EBITDA margin are helpful to our investors as they are measures used by management in assessing the health of our business, determining incentive compensation, evaluating our operating performance, and for internal planning and forecasting purposes.

Adjusted EBITDA is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Some of the limitations of Adjusted EBITDA include: (1) it does not properly reflect capital commitments to be paid in the future; (2) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures; (3) it does not consider the impact of stock-based compensation expense; (4) it does not reflect other non-operating expenses, including other income and interest (income) expense, net; (5) it does not reflect tax payments that may represent a reduction in cash available to us; and (6) it does not include legal fees associated with a vendor arbitration. In addition, our Adjusted EBITDA may not be comparable to similarly titled measures of other companies the measure the measure. Because of these limitations, when evaluating our performance, you should consider Adjusted EBITDA alongside other financial performance measures, including our net income from continuing operations and other GAAP results.

We calculate Adjusted EBITDA as net income, adjusted to exclude depreciation and amortization; stock-based compensation expense; other income; interest (income) expense, net; provision for income taxes; and legal fees associated with a vendo arbitration. We calculate Adjusted EBITDA margin as Adjusted EBITDA divided by revenue. Please see "Reconciliation of GAAP to Non-GAAP Financial Measures" in the appendix of this presentation.



Progyny at a glance

Our Mission:

To make any member's dream of parenthood come true through a **healthy**, **timely** and **supported** fertility journey

We Are:

A leading benefits manager specializing in carved out fertility and family building benefits

A differentiated approach to benefits plan design, member support, and active network management

Our members pursue the most effective treatment from the best physicians and **achieve optimal outcomes**

We Solve Important Problems:

Outdated plan designs achieving poor outcomes

High-risk maternity, NICU, and mental health expenses due to the lack of adequate

coverage and care management


Inequity and lack of inclusion in medical benefits

Poor recruitment, higher absenteeism & low retention

as fertility and family building benefits are becoming critical to attract and retain talent



Progyny's growth




1. As per our press release issued on August 5, 2021




Progyny investment highlights

- A leader in a large, growing and underpenetrated market
- Our differentiated model drives superior clinical outcomes at lower overall costs for our clients
- Expanding base of diversified, blue chip clients
- Sustainable competitive advantage
- Multiple levers for strong and significant organic growth
- Attractive financial model



The infertility market is large and growing



Source: Willis Towers Watson 2020 Emerging Trends in Health Care Survey – US (https://www.willistowerswatson.com/en-US/Insights/2020/05/employers-prioritize-family-friendly-benefits)
 Source: CDC data regarding the number of treatment cycles (https://www.cdc.gov/art/ardata/indea.html) and FertilityIQ's estimated cost per cycle (https://www.fertilityiq.com/topics/cost)
 As reported by the CDC for the period between 2014 to 2019, which is the most recent data available

The conventional approach to fertility benefits is broken

There are structural flaws in the conventional approach:

- Restrictive coverage and plan design
- Mandated step therapy
- Limited access to latest diagnostics and procedures
- Limited access to top fertility specialists
- Limited or no patient support
- Lack of pharmacy integration

These flaws have consequences to both patients <u>and</u> employers:

- Poor pregnancy rates
- High incidence of miscarriages and **MULTIPLE BIRTHS**
- Inefficient, ineffective use of healthcare dollars
- P&L volatility as a result of highcost claims
- Negative employee experience
- Poor presenteeism and retention rates

The costs to employers from pre-term births

(in addition to ineffective treatment costs)

~\$40 billion annually¹

7 PROPRIETARY & CONFIDENTIAL | NOT FOR DISTRIBUTION

1. ~\$34 billion in annual societal economic cost of preterm births in the US (2005 data published by the Institute of Medicine of the National Academies and as adjusted for inflation) and ~\$5.7 billion in annual estimated costs due to lost productivity (EMD Serono, Employers and Evidence Based Infertility Benefits http://resolve.org/wp-content/uploads/2017/09/employers-and-evidence-based-infertility-benefits.pdf)



Patient experience with conventional coverage yields sub-optimal experience and outcomes



Sarah has been trying to conceive

- She has a \$20K fertility benefit with mandated IUI
- She fails 3 cycles of IUI and exhausts most of her benefit



She takes out a loan to pay for IVF

- She pursues an IVF cycle
- She skips genetic testing to save money



She gets pregnant and miscarries

- She pursues a second IVF cycle
- She insists that multiple embryos be transferred



She delivers twins at 36 weeks via cesarean section

- Her employer incurs c-section & NICU costs
- Sarah takes an unplanned 9-month leave



Progyny has redefined fertility and family building benefits

Our Fertility Solution Our Superior Outcomes Differentiated benefits plan design For Members, Clients and **Our Data Platform** Providers: Personalized concierge-style member Faster time to pregnancy • support services Extensive data Fewer miscarriages ٠ collection and analysis Healthier pregnancies Selective network of high-quality fertility drives continuous ٠ specialists improvement More live births . Fewer twins and triplets ٠ Integrated pharmacy experience -Progyny Rx



Progyny drives life changing outcomes

| Progyny's unique approach | | | rior clinical resu ional averages | | and leads to: | | | | |
|---|--|---------------|--|--|---|------------------------------------|--------------|--|--|
| Personalized member support, NPS +79 | | 41% higher | Single embryo transfer (SET) rate ¹ | | 25 high | | 72% lower | | |
| Premier managed network of ~900 REIs | | | | live b rate | - | IVF multiples rate ² | | | |
| Comprehensive, equitable | | 16% higher | Pregnancy rate per IVF transfer ¹ | | Due eur | avery is the only company | | | |
| Smart Cycle plan design | | | | Progyny is the only company generating these outcomes and | | | | | |
| Integrated pharmacy experience with Progyny Rx, NPS +81 | | 26% lower | Miscarriage rate ¹ | | has 5 years of documented history doing so | | | | |
| - | | | | | | | | | |

Note: Progyny results represent in-network provider clinic averages for Progyny members only based on the 12-month period ended December 31, 2019. For each Progyny outcome presented, the p-value when compared to the national average is <0.0001

10 PROPRIETARY & CONFIDENTIAL | NOT FOR DISTRIBUTION

1 Calculated based on the Society for Assisted Reproductive Technology, or SART, 2017 National Summary Report, finalized in 2020 2 Calculated based on CDC, 2018 National Summary and Clinic Data Sets, published in 2020




Our outcomes generate measurable value for clients





Progyny's differentiated approach starts by carving out fertility from the carrier

- We carve out the fertility benefit while remaining integrated within the existing health plan
- We have integrations with all of the large national health insurance companies
- These integrations ensure that our benefits are provided on a pre-tax basis to members and are coordinated with the rest of their medical coverage for member responsibility



Differentiated benefits plan design

- Easy-to-understand Smart Cycle currency
- Replaces the dollar max concept with all-inclusive treatment bundles
- Empowers physicians to determine patient-specific treatment plans (no carrier mandates)
- Uses latest technologies and best practices
- Regularly reviewed by our Medical Advisory Board




Provides equitable access to treatment **Drives superior**

outcomes while

reducing costs

13 PROPRIETARY & CONFIDENTIAL | NOT FOR DISTRIBUTION

Smart Cycle Treatment Bundles



The Progyny patient experience yields optimal experience and outcomes



Sarah has been trying to conceive

 She has a 2 Smart Cycle Benefit through her employer



Her physician recommends IVF Freeze-All with a Frozen Embryo Transfer

- She uses 1 Smart Cycle (³/₄ + ¹/₄)
- It includes genetic testing and every service she needs
- She leverages Progyny's member support
- She transfers a single screened embryo





She delivers a healthy baby at 40.5 weeks

- Sarah takes her planned 4-month leave
- She has 1 Smart Cycle remaining for future transfers



Progyny's differentiated approach addresses racial disparities



- Our members receive personalized, culturally competent support
- Our plan design covers screening for monogenic disorders and approves PGT-M for trait carriers
- Our Smart Cycle currency allows physicians to customize the treatment pathway to each patient's unique needs



With the Smart Cycle, class and race bias are all but removed because all patients with [Progyny] coverage have equal access to the treatment they need.

Temeka Zore, MD









Personalized member support services

Highly experienced

Across all facets of fertility care: nurses, social workers, embryologists, andrologists, and clinical psychologists

Unlimited

Education and emotional support

15+ Interactions per member on average

- We believe that educated and supported patients make better treatment decisions
- Our Patient Care Advocates (PCAs) reduce stress, uncertainty, and the emotional strain that is often associated with a fertility journey
- PCAs are trained to support the unique needs of a diverse member population (LGBTQ+, single parents by choice)
- Members are matched to culturally competent providers

Net Promoter Score +81



Collaboration with a selective network of fertility specialists



Largest network of fertility specialists

- Includes 46 of the top 50 practice groups by volume
- Rigorous credentialing thresholds
- Network breadth facilitates matching members with the right physician for their unique circumstance



Active management of the network

- Providers contractually submit treatment and outcomes data
- Detailed quarterly clinical scorecards
- Drives superior outcomes
- Continuous quality improvement



Our Medical Advisory Board

- Comprised of leading fertility practitioners from across the country
- Advise on latest industry best practices
- Clinical guidance informs key business decisions





Integrated pharmacy experience: Progyny Rx

Reduce anxiety of medication administration and storage

- UnPack It[™] call with pharmacy clinician
- 24-7 support


Avoid missed cycles

- Single authorization
- Same or next day medication delivery

Specialty medication savings

- ~20% on the medication unit cost
- ~8% from waste management protocols

73% of clients have adopted Progyny Rx



Our growing list of diverse, bluechip clients reflects the universal need for fertility coverage

| Our clier | nts are | in over | 25 | different | industries, |
|-----------|---------|---------|----|-----------|-------------|
| including | 5: | | | | |


| Technology | Financial Services |
|--|--|
| Consumer Packaged Goods | Industrial and Manufacturing |
| Telecommunications | • Energy |
| Healthcare | Professional Services |
| Transportation | Software |
| Education | Pharmaceutical |

Our growth has been enhanced as employers across industries recognize the positive contribution Progyny makes to their DEI initiatives






19




Multiple levers for strong and significant growth





Progyny's attractive financial model





Progyny Overview

Appendix: Reconciliation of GAAP to Non-GAAP Financial Measures

| | Year Ended December 31, | | | | | | | | | Reconciliation of Anticipated Net Income to Anticipated Adjusted EBITDA for the Year Ended December 31, 2021 ¹ | | | |
|--|-------------------------|----|----------|----|---------|----|---------|----|----------|---|---------|----|---------|
| (in thousands) | 2016 | | 2017 | | 2018 | | 2019 | | 2020 | | Low | | High |
| Net (loss) income from continuing operations | \$ (11,833) | \$ | (12,456) | \$ | (5,116) | \$ | (8,569) | \$ | 46,459 | \$ | 43,200 | \$ | 50,400 |
| Add: | | | | | | | | | | | | | |
| Depreciation and amortization | 1,700 | | 1,559 | | 1,883 | | 2,135 | | 1,906 | | 1,600 | | 1,400 |
| Stock-based compensation expense | 728 | | 1,559 | | 2,997 | | 5,061 | | 12,821 | | 26,000 | | 25,000 |
| Other income | - | | - | | - | | - | | (210) | | - | | - |
| Interest expense (income), net | 1,065 | | 740 | | 497 | | 58 | | (121) | | (300) | | (300) |
| Convertible preferred stock warrant valuation adjustment | (741) | | 714 | | 2,944 | | 18,176 | | - | | - | | - |
| Provision (benefit) for income taxes | (3,028) | | (3) | | (1,777) | | 12 | | (37,780) | | (3,000) | | (4,000) |
| Settlement cost and legal fees associated with a vendor | - | | - | | - | | 1,319 | | 9,318 | | - | | - |
| Non-deferred IPO Costs | - | | - | | - | | 150 | | - | | - | | - |
| Adjusted EBITDA | \$ (12,109) | \$ | (7,887) | \$ | 1,428 | \$ | 18,342 | \$ | 32,393 | \$ | 67,500 | \$ | 72,500 |

Adjusted EBITDA Margin on Incremental Revenue Calculation

| | Twelve Months Ended December 31, | | | | | |
|---|----------------------------------|---------|------|---------|--|--|
| | | 2020 | 2019 | | | |
| Revenue | \$ | 344,858 | \$ | 229,683 | | |
| | | | | | | |
| Adjusted EBITDA | \$ | 32,393 | \$ | 18,342 | | |
| | | | | | | |
| Incremental revenue vs. 2019 | \$ | 115,175 | | | | |
| | | | | | | |
| Incremental Adjusted EBITDA vs. 2019 | \$ | 14,051 | | | | |
| Add: | | | | | | |
| One time step-up in incremental public company expenses | | 5,186 | | | | |
| Incremental Adjusted EBITDA excluding one-time step-up in | | | | | | |
| incremental public company expenses | \$ | 19,237 | | | | |
| Incremental Adjusted EBITDA margin on incremental revenue | | | | | | |
| excluding one-time step-up in incremental public company | | | | | | |
| expenses | | 16.7% | | | | |

1. Reflects the guidance ranges provided in our August 5, 2021 press release and is as of August 5, 2021; Net income and Adjusted EBITDA ranges do not reflect any estimate for other potential activities and transactions, nor do they contemplate any discrete income tax items, including the income tax impact related to equity compensation activity.

2. We engaged in other activities and transactions that can impact our net income. In recent periods, these other items included, but were not limited to, legal fees related to an arbitration resulting from our termination of an agreement with a specialty pharmacy vendor and its settlement in the fourth quarter of 2020.